Assessing the safety and cost-effectiveness of early nanodrugs
This article provides a detailed examination of how the safety and cost-effectiveness elements of Australia's drug regulatory system will respond to nanomedicines. The case study investigated involves Abraxane, a newly developed anti-cancer agent. The article concludes by proposing some responses to the challenges which nanomedicines are likely to present to international and domestic agencies. Additionally, it considers whether the recommendation of the Australian Productivity Commission to...[Show more]
|Collections||ANU Research Publications|
|Source:||Journal of Law and Medicine|
|01_Faunce_Assessing_the_safety_and_2009.pdf||159.85 kB||Adobe PDF||Request a copy|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.